2 blue chip healthcare shares you should own

Every investor should consider these 2 healthcare giants.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

a woman

The economy is made up of a number of different sectors and businesses. The healthcare industry is one of the best sectors to invest your money in my opinion.

Here are a few reasons why you should consider Cochlear Limited (ASX: COH) and CSL Limited (ASX: CSL).

Defensive earnings

Healthcare offers shareholders a defensive earnings profile because of how integral the product or service is.

People will value being alive and healthy over most other things in life.

CSL offers a variety of services like plasma products, vaccines and pharmaceuticals which users will all value over a trip to the movies and other lifestyle expenses.

Cochlear gives its users a life changing ability to improve their hearing with hearing implants.

Ageing demographics

There is a unique set of circumstances happening now and over the next few decades where the population of people older than 65 is going to significantly increase. This should be a big boost to all the companies that benefit from elderly customers. Cochlear and CSL could be two of the biggest winners.

International expansion

Australia has a small population and it doesn't offer much room for growth. If a business can successfully expand overseas then the world becomes their oyster.

CSL and Cochlear both earn a large majority of their earnings from overseas and I imagine this will continue to be the case as they grow in Europe and North America.

Time to buy?

Cochlear is trading at 38x FY18's estimated earnings and CSL is trading at 30x FY18's estimated earnings.

Both shares are wonderful businesses but I don't think they're buys at the current prices. I'd wait until they're both at least 15% to 20% cheaper before buying over the next six months.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »